Register with Team Alopecia to get a monthly email update on alopecia related news, research, meetings, events & fundraisers; and to post your comments and reviews. We will never sell or share your information or email address in any way.
You may qualify to participate in a clinical research study involving the
investigational use of bimatoprost (Lumigan ®) ophthalmic drops in promoting
eyelash growth in patients with eyelash loss due to alopecia areata.
Bimatatoprost ophthalmic solution is approved for the treatment of glaucoma.
Patients who are treated for glaucoma with this medication often notice longer,
thicker eyelashes. Currently, there are no safe or acceptable treatments for
eyelash loss due to alopecia areata.
You may qualify to participate in this study if you:
• Are between the
ages of 18 - 70
• Have 50% or more eyelash loss in both eyes due to alopecia
areata which has been
present for 6 months or longer.
All office visits, ophthalmologic examinations, photographs, and study drug
will be provided without charge. There is no compensation for time or
travel.
If you live in the vicinity of the location listed below and would like to
find out if you qualify to be a participant, or if you have further questions
about this study, please call the investigator below.
Investigator Location Contact
Vera H. Price, M.D. University of
California, San Francisco
San Francisco, CA Blanca E. Ochoa, M.D.
(415)
353-9529
Email:
This email address is being protected from spam bots, you need Javascript enabled to view it
The purpose of this study is to examine prospectively the safety and efficacy of
Botulinum Toxin A (Botox) injections in the treatment of patients with alopecia
areata of the scalp.
Eligibility
Ages Eligible for Study: 19 Years
- 65 Years, Genders Eligible for Study: Both
Inclusion Criteria:
Patients with long standing alopecia areata,
patches must be at least 4 cm in diameter
Exclusion Criteria:
Intake of drugs that interfere with Botulinum toxin
A such as gentamicin, tobramycin, clindamycin and lincomycin; medications used
to treat heart rhythm problems, such as quinidine; and medications used to treat
other conditions, such as myasthenia gravis, ALS or Alzheimer's disease.
Neuromuscular disorders such as Myasthenia gravis and
Lambert-Eaton-Syndrome.
Treatment with another investigational drug within 4 weeks prior to
anticipated first treatment.
Females who are pregnant, planning to become
pregnant during the study period, or breastfeeding.
(This study was confirmed as not yet recruiting as of December of 2006. But the study was set to begin recruiting in January of 2007, so if you are interested you should look into contacting the study investigators using the contact info supplied in the link.)
The goals of this study are to
understand the genetic control of autoimmunity in alopecia areata (AA), to
better understand the complex biology of the cycling hair follicle, and to use
this knowledge to devise safe and effective treatments for this common disease.
Eligibility
Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
All patients with AA, children and adults, who have
been diagnosed by a dermatologist, who is an expert in the field of alopecia.
Subtypes that are allowable are alopecia universalis, alopecia totalis, patchy
persistent alopecia or transient mild alopecia.
Family members, related by blood, of these patients (preferably sib-pairs
plus parents and multiplex families).
Age matched controls from spouses or clinic
patients
Exclusion Criteria:
A person under the age of 18 years not accompanied
by parent or guardian.
A person who is unable to comprehend the informed
consent and sign the consent form.
Alopecia areata is the loss of hair in patches that can proceed to loss of all
hair (alopecia totalis or universalis). The purpose of the registry is to
collect patient information and blood samples from people with alopecia areata.
This genetic study will involve a comprehensive, genome-wide screen of DNA
isolated from blood samples provided by donors. Statistical analysis of the
results will provide information on areas of the human genome where genes
involved in AA are located. With this information, and using data from the
recently completed human genome mapping project, candidate genes can later be
defined and examined in detail to evaluate how they may be involved in alopecia
areata.
Eligibility
This study needs the participation of at least 1120 volunteers in 280 family
groups to ensure reliable results. We need to obtain blood samples from at least
4 people in a family (Mother and Father and 2 children).
Specific volunteer requirements:
You must have (or have had) alopecia areata and be willing to provide a
blood sample.
You must have a genetically related brother or sister who has (or has had)
alopecia areata and is willing to provide a blood sample.
You and your brother or sister must not be monozygotic twins (identical
twins).
It is not necessary for your genetically related mother and father to have
alopecia areata, but they must be willing to each provide a blood sample.
Individuals with trisomy 21 (Down's syndrome) are not able to take part in
the study as the additional chromosome 21 DNA would bias the statistical
analysis.
You should be resident in Europe, Scandinavia, Taiwan, Australia, or
Singapore. We are currently investigating methods to include individuals from
other geographic regions, but at this time we have no system to collect blood or
data from volunteers located outside Europe, Scandinavia, Taiwan, Australia, and
Singapore.
The purpose of this investigation is to study the effectiveness of longer
wavelength UVA1 (340-400nm) or shorter wavelength ultraviolet B [UVB]
(290-320nm) irradiation in the treatment of inflammatory skin conditions (such
as: atopic dermatitis, psoriasis, mycosis fungoides, alopecia areata, stretch
marks and urticaria).
This research study aims to evaluate the effectiveness of an investigational
device which is similar in appearance to a “tanning bed” but which emits
ultraviolet irradiation of a specific wavelength known as UVA1. This device has
not been approved by the Food and Drug Administration (FDA) for general use in
this country, as of yet, but it has been used quite successfully in Europe for
several years in treating such conditions as scleroderma, atopic dermatitis,
urticaria pigmentosa and other skin conditions.
Instead of UVA1 therapy, patients may receive ultraviolet radiation of a
specific wavelength known as UVB. UVA1 light is a longer wavelength and
therefore a lower energy wavelength than UVB. UVB light is often the light
associated with getting a sunburn since it has a higher level of energy. UVB
light has been used successfully in the treatment of many skin conditions.
Eligibility
Ages Eligible for Study: 10 Years
- 80 Years, Genders Eligible for Study: Both
Inclusion Criteria:
Ages: 10-80 years
Clinical diagnosis of inflammatory dermatoses such as atopic dermatitis,
psoriasis, mycosis fungoides, alopecia areata, and urticaria.
No disease states or physical conditions that would impair evaluation of the
test site.
Willing and able to receive UVA1 or UVB, as directed in the protocol; make
evaluation visits; and follow protocol restrictions.
The purpose of this study is to
examine prospectively the safety and efficacy of alefacept in the treatment of
subjects with severe alopecia areata of the scalp. Common features between
psoriasis and alopecia areata, including immunologic and therapeutic aspects,
suggest that alefacept, which has been shown to be a safe and statistically
significant beneficial therapeutic modality for the treatment of psoriasis, may
have therapeutic value in alopecia areata.
Eligibility
Ages Eligible for Study: 18 Years
- 65 Years, Genders Eligible for Study: Both
Accepts Healthy Volunteers
Inclusion Criteria:
Subjects must give written informed consent and
candidates in the US must authorize the release and use of protected health
information (PHI)
Subjects must be between the ages of 18 and 65 inclusive at the time of
informed consent
Must have a diagnosis of scalp alopecia areata as determined by the study
investigator
Must have 50-95% patchy scalp hair loss due to alopecia areata of at least
one year duration
Must have CD4+ T-lymphocyte counts at or above
the lower limit of normal as determined by a local laboratory.
Exclusion Criteria:
History of systemic or cutaneous malignancy other
than treated basal cell carcinomas or 3 or less squamous cell carcinomas.
Nevi or cutaneous lesions currently undiagnosed but suspicious for
malignancy.
Evidence of immunocompromise.
Advanced or poorly controlled diabetes.
Unstable cardiovascular disease.
Clinically significant medical or psychiatric disease as determined by the
investigator.
History of alcohol or drug abuse within 2 years of assessment for study
enrollment.
Serious local infection (e.g. cellulitis, abscess) or systemic infection
(e.g. pneumonia, septicemia) within 3 months prior to the first dose of
investigational drug.
Positive PPD history of incompletely treated or untreated tuberculosis.
Abnormal T-lymphocyte count, and/or liver function tests.
If female, serum hemoglobin level greater than 1 unit below accepted limit
for normal or otherwise abnormal.
Male subjects with an abnormal serum hemoglobin.
Known positivity for hepatitis C antigen or hepatitis B surface antigen.
Known positivity for HIV antibody.
Diagnosis of diffuse alopecia areata.
Coexistent androgenetic alopecia which, in males is Norwood-Hamilton stage
VI or greater, or in females, Ludwig stage III.
Prior treatment with alefacept.
Treatment with another investigational drug within 4 weeks prior to
anticipated first treatment dose.
Unable to practice effective contraception for the duration of the study.
Females who are nursing, pregnant or planning to become pregnant while in
the study.
Those who have donated blood within a month of date of screening evaluation.
Concomitant enrollment in other investigational drug study.
Unwilling to maintain a consistent hair style and to eschew shaving of scalp
hair throughout the course of the study.
Unable to comply with the protocol.
Other unspecified reasons that contraindicate
enrollment in the study, as determined by the study investigator.
"One theory on the cause of alopecia areata is that it is due to a collapse of hair follicle immune privilege. Normal hair follicles rely on their immune privilege to grow. Dr Hope Dinh is currently undertaking a Doctor of Medicine thesis at the University investigating the role of hair follicle immune privilege in hair growth. We are seeking volunteers who are prepared to have a scalp biopsy. Ideally, we would like people with patches of alopecia areata rather than total hair loss".
If you are interested in participating, please contact Dr Hope Dinh at 0402 944 588 or by email at
This email address is being protected from spam bots, you need Javascript enabled to view it
Wig Site Reviews
